COMPASS Pathways plc Banner Image

COMPASS Pathways plc

  • Ticker CMPS
    Exchange NASDAQ More
  • Industry Health Care Plans More
  • Sector Healthcare More
COMPASS Pathways plc Logo Image
  • 51-200 Employees
  • Based in London, England
COMPASS Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Their focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. They are pioneering the development of a new model of psilocybin therapy, in which their proprietaryMore formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). They have commenced a phase 3 clinical program of COMP360 psilocybin therapy in TRD, the largest randomized, controlled, double-blind psilocybin therapy clinical program ever conducted. Previously, they completed a phase 2b study with top line data showing a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single 25mg dose of COMP360 psilocybin with psychological support. They are also conducting phase 2 clinical studies of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD) and anorexia nervosa. COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the United States. Their vision is a world of mental wellbeing.
COMPASS Pathways plc

Most Recent Annual Report

COMPASS Pathways plc
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

COMPASS Pathways plc Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!